US2002119487A1PendingUtilityA1

Human stem cell antigen 2

55
Priority: Nov 9, 1995Filed: Mar 21, 2002Published: Aug 29, 2002
Est. expiryNov 9, 2015(expired)· nominal 20-yr term from priority
Inventors:Jian NiGuo-Liang YuReiner GentzJeannine D. Gocayne
A61K 38/00C07K 14/705
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A human stem cell antigen 2 polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for stimulating thymocyte maturation and differentiation, protecting neuronal cells, preventing rejection during organ transplantation, treating PNH, Alzheimer's Disease and inflammation is disclosed. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases, for example, cancer, are also disclosed.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . An isolated polynucleotide comprising a polynucleotide having at least 95% identity to a member selected from the group consisting of: 
 (a) a polynucleotide encoding a polypeptide comprising amino acid 1 to 82 of SEQ ID NO:2; and    (b) the complement of (a).    
     
     
         2 . The isolated polynucleotide of  claim 1  wherein said member is (a).  
     
     
         3 . The isolated polynucleotide of  claim 1  wherein said member is (a) and the polypeptide comprises amino acids 1 to 111 of SEQ ID NO:2.  
     
     
         4 . The isolated polynucleotide of  claim 1  wherein said member is (a) and the polypeptide comprises amino acids −20 to 111 of SEQ ID NO:2.  
     
     
         5 . The isolated polynucleotide of  claim 1  comprising a polynucleotide encoding a polypeptide comprising the amino acid sequence identical to amino acids 2 to 82 of SEQ ID NO:2.  
     
     
         6 . The isolated polynucleotide of  claim 1 , wherein the polynucleotide is DNA.  
     
     
         7 . The isolated polynucleotide of  claim 1  comprising a polynucleotide encoding a polypeptide comprising the amino sequence identical to amino acids 1 to 111 of SEQ ID NO:2.  
     
     
         8 . The isolated polynucleotide of  claim 1 , wherein said polynucleotide is RNA.  
     
     
         9 . A method of making a recombinant vector comprising inserting the isolated polynucleotide of  claim 2  into a vector, wherein said polynucleotide is DNA.  
     
     
         10 . A recombinant vector comprising the polynucleotide of  claim 2 , wherein said polynucleotide is DNA.  
     
     
         11 . A recombinant host cell comprising the polynucleotide of  claim 2 , wherein said polynucleotide is DNA.  
     
     
         12 . A method for producing a polypeptide comprising expressing from the recombinant cell of  claim 11  the polypeptide encoded by said polynucleotide.  
     
     
         13 . A process for producing a polypeptide comprising: 
 expressing from a recombinant cell containing the polynucleotide of  claim 5  the polypeptide encoded by said polynucleotide.    
     
     
         14 . A process for producing a polypeptide comprising: 
 expressing from a recombinant cell containing the polynucleotide of  claim 7  the polypeptide encoded by said polynucleotide.    
     
     
         15 . The isolated polynucleotide of  claim 1  comprising nucleotides 202 to 534 of SEQ ID NO:1.  
     
     
         16 . The isolated polynucleotide of  claim 1  comprising nucleotides 142 to 534 of SEQ ID NO:1.  
     
     
         17 . The isolated polynucleotide of  claim 1  comprising nucleotides 202 to 447 of SEQ ID NO:1.  
     
     
         18 . The isolated polynucleotide of  claim 1  comprising the nucleotides of the sequence of SEQ ID NO:1.  
     
     
         19 . An isolated polynucleotide comprising a polynucleotide having at least a 95% identity to a member selected from the group consisting of: 
 (a) a polynucleotide encoding the same mature polypeptide encoded by the human cDNA in ATCC Deposit No. 97301; and    (b) the complement of (a).    
     
     
         20 . The isolated polynucleotide of  claim 19 , wherein the member is (a).  
     
     
         21 . The isolated polynucleotide of  claim 19 , wherein said polynucleotide comprises DNA identical to the coding portion of the human cDNA in ATCC Deposit No. 97301 which encodes a mature polypeptide.  
     
     
         22 . An isolated polypeptide comprising: 
 a mature polypeptide having an amino acid sequence encoded by a polynucleotide which is at least 95% identical to the polynucleotide of  claim 5 .    
     
     
         23 . The isolated polypeptide of  claim 22 , comprising amino acids 2 to 82 of sequence of SEQ ID NO:2.  
     
     
         24 . The isolated polypeptide of  claim 22 , comprising amino acids 1 to 111 of sequence of SEQ ID NO:2.  
     
     
         25 . The isolated polypeptide of  claim 22  comprising amino acids −20 to 111 of SEQ ID NO:2.  
     
     
         26 . An isolated polypeptide comprising: 
 a mature polypeptide encoded by a polynucleotide which is at least 95% identical to the human cDNA contained in ATCC Deposit No. 97301.    
     
     
         27 . The isolated polypeptide of  claim 26  comprising the mature polypeptide encoded by the human cDNA in ATCC Deposit No. 97301.  
     
     
         28 . An antibody against the polypeptide of  claim 22 .  
     
     
         29 . An antagonist against the polypeptide of  claim 22 .  
     
     
         30 . A method for the treatment of a patient having need of a hSca-2 protein comprising: administering to the patient a therapeutically effective amount of the polypeptide of  claim 22 .  
     
     
         31 . The method of  claim 27  wherein said therapeutically effective amount of the polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide in vivo.  
     
     
         32 . A method for the treatment of a patient having need to inhibit a hSca-2 protein polypeptide comprising: 
 administering to the patient a therapeutically effective amount of the compound of  claim 29 .    
     
     
         33 . A process for diagnosing a disease or a susceptibility to a disease related to an under-expression of the polypeptide of  claim 22  comprising: 
 determining a mutation in a nucleic acid sequence encoding said polypeptide.  
 
     
     
         34 . A diagnostic process comprising: analyzing for the presence of the polypeptide of  claim 22  in a sample derived from a host.  
     
     
         35 . A method for identifying compounds which bind to and inhibit activation of the polypeptide of  claim 22  comprising: 
 contacting a cell expressing on the surface thereof a receptor for the polypeptide, said receptor being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said receptor, with an analytically detectable mammary transforming protein and a compound under conditions to permit binding to the receptor; and  
 determining whether the compound binds to and inhibits the receptor by detecting-the absence of a signal generated from the interaction of the hSca-2 protein with the receptor.  
 
     
     
         36 . An isolated polynucleotide comprising a member selected from the group consisting of: 
 (a) DNA having a sequence of at least 15 consecutive bases, which sequence is at least 95% complementary to a member selected from the group consisting of: 
 (i) DNA having at least 15 consecutive bases from nucleotide 1 to nucleotide 1157 of SEQ ID NO:1;  
 (ii) DNA complementary to (i); and  
   (b) RNA corresponding to the DNA of (a).    
     
     
         37 . The isolated polynucleotide of  claim 36  wherein said member is (a).  
     
     
         38 . The isolated polynucleotide of  claim 36  wherein said member is (b).  
     
     
         39 . The isolated polynucleotide of  claim 37  wherein said member is (a) and said 15 consecutive bases are selected from the sequence of nucleotides 142 to 534.  
     
     
         40 . An isolated polynucleotide comprising a member selected from the group consisting of: 
 (a) DNA having a sequence of at least 15 consecutive bases, which sequence is at least 95% complementary to a member selected from the group consisting of: 
 (i) DNA having at least 15 consecutive bases from the portion of the cDNA of ATCC Deposit No. 97301 which encodes for hSca-2;  
 (ii) DNA complementary to (i); and  
   (b) RNA corresponding to the DNA of (a).    
     
     
         41 . The isolated polynucleotide of claim  40  wherein said member is (a).  
     
     
         42 . The isolated polynucleotide of claim  40  wherein said member is (b).

Join the waitlist — get patent alerts

Track US2002119487A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.